Clinical Oncology
Volume 16, Issue 8 , Pages 543-548, December 2004

The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence guidance 2001: the Nottingham experience

  • A. Anand
    • ,
  • S.Y. Chan

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: Dr Stephen Y. Chan, Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK. Tel: +44-115-9691169, ext 47298; Fax: +44-115-9628047.

Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham, UK

Received 22 December 2003; received in revised form 22 June 2004; accepted 6 July 2004.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0936-6555(04)00258-4

doi:10.1016/j.clon.2004.07.003

Clinical Oncology
Volume 16, Issue 8 , Pages 543-548, December 2004

Article Tools